Legend Biotech Corp(LEGN)Stock Analysis
AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →13F Pro Quality Score
Rank #1,781 of 2,879 stocks
Rankings refresh quarterly once 80% of peers have filed (~45 days after quarter-end). Next update: ~Aug 14, 2026.
Revenue Growth
Profitability
Balance Sheet
Earnings Quality
Free Cash Flow
Institutional Flow
Revenue Scale
Dilution Risk
LEGN Stock Analysis & AI Quality Score
AI stock analysis and institutional research for Legend Biotech Corp (LEGN), a Healthcare sector company. 13F Pro's AI-powered ranking engine scores LEGN at 44.2/100 on a 32-signal composite quality model, placing it at rank #1,781 of 2,879 stocks — the bottom half of the AI-ranked universe. LEGN scores in the top quartile across revenue growth (93.0), institutional flow (78.9). Areas of concern include balance sheet strength (10.5) and profitability (11.4), which score below median versus the broader universe. Based on the latest XBRL financial filings (Q3 2025), Legend Biotech Corp reports quarterly revenue of $272.4M, net income of $-39.7M. Top institutional holders of LEGN by reported 13-F value include FMR, DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C), SUVRETTA CAPITAL MANAGEMENT,, based on the most recent SEC filings. LEGN trades on the Nasdaq exchange and files with the SEC under CIK 1801198. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate LEGN daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Legend Biotech Corp directly from SEC EDGAR. Legend Biotech Corp's 13F Pro composite quality score has ranged between 23 and 44 since 2024, currently 44.2 — an improving long-term trajectory across 15 quarterly and live scoring snapshots.
Revenue
Q3 2025
$272.4M
Net Income
Q3 2025
$-39.7M
Get alerted when LEGN's score changes
Free account: watchlist tracking, the daily AI brief, and the AI screener.
Available Research
13F Pro tracks comprehensive data for Legend Biotech Corp including:
Top Institutional Holders of LEGN
FMR LLC
$464.9M25,696,740 shDEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C)
$139.1M7,687,638 shSUVRETTA CAPITAL MANAGEMENT, LLC
$137.1M7,581,029 shHillhouse Capital Advisors, Ltd.
$108.3M5,984,550 shWESTFIELD CAPITAL MANAGEMENT CO LP
$104.3M5,763,475 shBlackRock, Inc.
$84.7M4,684,543 shPoint72 Asset Management, L.P.
$70.3M3,886,017 shFirst Beijing Investment Ltd
$41.5M2,296,335 shArtisan Partners Limited Partnership
$40.8M2,254,488 shTWO SIGMA INVESTMENTS, LP
$34.2M1,890,396 sh
| Fund | Value | Shares |
|---|---|---|
| FMR LLC | $464.9M | 25,696,740 |
| DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) | $139.1M | 7,687,638 |
| SUVRETTA CAPITAL MANAGEMENT, LLC | $137.1M | 7,581,029 |
| Hillhouse Capital Advisors, Ltd. | $108.3M | 5,984,550 |
| WESTFIELD CAPITAL MANAGEMENT CO LP | $104.3M | 5,763,475 |
| BlackRock, Inc. | $84.7M | 4,684,543 |
| Point72 Asset Management, L.P. | $70.3M | 3,886,017 |
| First Beijing Investment Ltd | $41.5M | 2,296,335 |
| Artisan Partners Limited Partnership | $40.8M | 2,254,488 |
| TWO SIGMA INVESTMENTS, LP | $34.2M | 1,890,396 |
More Healthcare Companies
View all Healthcare →Put LEGN on your watchlist
Track score changes the day Legend Biotech Corp files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.
Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).
Popular Research
Is LEGN a good stock to buy?
13F Pro's AI-powered analysis of Legend Biotech Corp (LEGN) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for LEGN are available on the LEGN stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing.
Which hedge funds own LEGN?
Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling LEGN. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of Legend Biotech Corp's investment landscape.